A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

Kmet, Leanne; Cook, Linda S.; Magliocco, Anthony M.

doi:10.1002/cncr.11064

Cited by 97 publications

(81 citation statements)

References 110 publications

(147 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mutations of p53 are frequently detected in ovarian cancer (Crook et al, 1992;Kmet et al, 2003). Consistent with those studies, we found that 42% of ovarian cancers were p53 positive.…”

Section: Discussionsupporting

confidence: 91%

Detection of human papillomavirus-16 in ovarian malignancy

Guo

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

Human papillomavirus is the causal factor for cervical cancer. However, the role of HPV infection in ovarian cancer is unclear. This study aimed to determine the presence of human papillomavirus-16 (HPV-16) in ovarian cancer tissues. Archived human ovarian cancer tissues (N ¼ 54 cases, 50 are epithelial cancer, four are nonepithelial cancer) embedded in paraffin blocks were used. Controls are 30 nonmalignant ovarian tissue blocks. In situ hybridisation (ISH) and immunohistochemistry (IHC) were used to detect the presence of HPV-16 and p53 expression. In all, 52 or 36% of the epithelial ovarian tumours detected by ISH or IHC, respectively, were HPV-16 E6 positive. In contrast, only 6.7% of normal ovarian tissues were HPV-16 positive proved by ISH. Human papillomavirus-16 infection was significantly higher in cancer tissues compared to controls with an odds ratio of 16.7 (95% confidence interval [CI] ¼ 3.2 -71.4, Po0.01). No significant correlation between HPV-16 infection and histological types of cancer was found (P40.05). p53 gene expression was detected in 42% epithelial ovarian cancers. No correlation between p53 expression and HPV-16 infection was found. The results showed the presence of HPV-16 E6 in ovarian carcinoma, suggesting that HPV infection might play a role in ovarian carcinogenesis.

show abstract

“…Mutations of p53 are frequently detected in ovarian cancer (Crook et al, 1992;Kmet et al, 2003). Consistent with those studies, we found that 42% of ovarian cancers were p53 positive.…”

Section: Discussionsupporting

confidence: 91%

Detection of human papillomavirus-16 in ovarian malignancy

Guo

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…This concept is reinforced by the fact that higher MCM-2 and MCM-5 LIs were observed in the 32 (47.8% of cases) ovarian adenocarcinomas with p53 LI more than 10%, a cutoff that that has been shown to be efficient for the identification of p53 mutations in paraffin blocks staining (Banks et al, 1986). According to a recent study, p53 mutation prevalence estimates were 45, 5 and 1%, respectively, for invasive, LMP and benign ovarian tumours (Reles et al, 2001;Kmet et al, 2003). As opposed to carcinomas, no relation was established between p53 and cell proliferation markers in LMP tumours.…”

Section: Discussionmentioning

confidence: 99%

Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications

et al. 2007

View full text Add to dashboard Cite

Minichromosome maintenance proteins (MCM) have recently emerged as novel proliferation markers with prognostic implications in several tumour types. This is the first study investigating MCM-2 and MCM-5 immunohistochemical expression in a series of ovarian adenocarcinomas and low malignant potential (LMP) tumours aiming to determine possible associations with clinicopathological parameters, the conventional proliferation index Ki-67, cell cycle regulators (p53, p27 Kip1 , p21 WAF1 and pRb) and patients' outcome. Immunohistochemistry was applied in a series of 43 cases of ovarian LMP tumours and 85 cases of adenocarcinomas. Survival analysis was restricted to adenocarcinomas. The median MCM-2 and MCM-5 labelling indices (LIs) were significantly higher in adenocarcinomas compared to LMP tumours (Po0.0001 for both associations). In adenocarcinomas, the levels of MCM-2 and MCM-5 increased significantly with advancing tumour stage (P ¼ 0.0052 and P ¼ 0.0180, respectively), whereas both MCM-2 and MCM-5 increased significantly with increasing tumour grade (P ¼ 0.0002 and P ¼ 0.0006, respectively) and the presence of bulky residual disease (Po0.0001 in both relationships). A strong positive correlation was established between MCM-2 or MCM-5 expression level and Ki-67 LI (Po0.0001) as well as p53 protein (P ¼ 0.0038 and P ¼ 0.0500, respectively). Moreover, MCM-2 LI was inversely correlated with p27KipÀ1 LI (P ¼ 0.0068). Finally, both MCM-2 and MCM-5 were associated significantly with adverse patients' outcome in both univariate (X20 vs 420%, P ¼ 0.0011 and X25 vs o25%, P ¼ 0.0100, respectively) and multivariate (P ¼ 0.0001 and 0.0090, respectively) analysis. An adequately powered independent group of 45 patients was used in order to validate our results in univariate survival analysis. In this group, MCM-2 and MCM-5 expression retained their prognostic significance (Po0.0001 in both relationships). In conclusion, MCM-2 and MCM-5 proteins appear to be promising as prognostic markers in patients with ovarian adenocarcinomas.

show abstract

“…In line with data reported in the literature, in our cohort of patients we observed a trend relating p53 status and overall survival, although the relatively small sample size suggests that these data have to be interpreted with caution. 19,20 Thus, molecular-prognostic analyses of ovarian carcinomas fail to provide a clear picture. The main reason for this situation may be that most studies were focused on p53 only and/or restricted to a small sample size with generally a high stage of malignancy.…”

Section: Discussionmentioning

confidence: 99%

Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer

Marabese

Marchini

Marrazzo

et al. 2008

European Journal of Cancer

View full text Add to dashboard Cite

The p53 gene has been investigated for its role in epithelial ovarian cancer but data collected until now are contradictory. The evidence that p53 belongs with p63 and p73 to a family of transcription factors re-opened interest in this gene family.Here, we used quantitative real time RT-PCR to determine expression levels of TAp53, TAp73 and their N-terminal splice variants in a cohort of 169 ovarian cancer patients with stage I and stage III disease. The TAp73 levels in stage III biopsies differed by 100-fold depending on the p53 status and overall survival appears to be significantly related to ΔNp73 expression. Kaplan-Meyer analyses did not suggest a correlation between overall survival and levels of TAp73, ΔNp73 or the ΔNp73/TAp73 ratio. In conclusion, these data suggest that at least in our patient cohort p53 and p73 expression levels are not correlated to malignant progression of ovarian cancer. They might, however, play a role in tumour initiation.

show abstract

A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors

Cited by 97 publications

References 110 publications

Detection of human papillomavirus-16 in ovarian malignancy

Detection of human papillomavirus-16 in ovarian malignancy

Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications

Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer

Contact Info

Product

Resources

About